BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Mabwell Doses First Patient In United States First In Human Trial Of Novel CDH17 Targeting ADC For Gastrointestinal Cancers

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

January 26, 2026 | News

Ellipses Pharma Limited In Licences First In Class B7H3 Targeted ADC From Innolake Biopharm Co. Ltd To Expand Global Oncology Pipeline

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced th...

January 26, 2026 | News

Gene Solutions And Pangea Laboratory Partner To Advance US Clinical Validation Of Liquid Biopsy Tests

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive ...

January 22, 2026 | News

Samsung Biologics Strengthens Long Term Growth Platform With Solid 2025 Financial Performance

Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent ...

January 22, 2026 | Company results

Alcami Expands Research Triangle Presence With Acquisition Of Durham Laboratory Facility

Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), has acquired a 37,000-square-foot facility at 4620 Cre...

January 21, 2026 | News

Alteogen Signs Exclusive Global Licensing Deal With GSK Subsidiary Tesaro For ALT B4

Alteogen Inc. (KOSDAQ: 196170) announced that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK...

January 21, 2026 | News

Ascletis Selects Once Monthly Triple Agonist ASC37 As Clinical Development Candidate For Obesity

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, whic...

January 21, 2026 | News

From Capacity to Capability: How 2026 can be the catalyst for what APAC’s Biopharma Growth Needs Next

Beyond Scale: What Will Sustain APAC’s Biopharma Leadership Asia-Pacific’s rise in global biopharma is no longer about whether the region can ...

January 21, 2026 | News | By Joonho Choi, Vice President, Asia-Pacific, Cytiva

Harbour BioMed Strengthens Strategic Ties With Spruce Biosciences Through Equity Stake

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in imm...

January 20, 2026 | News

AstraZeneca Acquires Full Global Rights To CCAR031 From AbelZeta Pharma

AbelZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietar...

January 20, 2026 | News

D3 Bio Secures FDA IND Clearances To Advance KRAS G12D And G12C Clinical Programme

D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, announced that the U.S. Foo...

January 20, 2026 | News

Dr Chris Chen Positions WuXi Biologics As The Defining Force Shaping The Future Of Global CRDMO Innovation

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects ...

January 19, 2026 | News

Fresenius Kabi And TQ Therapeutics Sign Strategic Agreement To Scale T Cell Manufacturing For Cell And Gene Therapy

Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under...

January 16, 2026 | News

Animate Biosciences Delivers Ai Designed Peptides That Match Standard Of Care In Pulmonary Fibrosis Model

Animate Biosciences announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeu...

January 15, 2026 | News

Stay Connected